{"id":144141,"date":"2023-04-25T10:27:00","date_gmt":"2023-04-25T14:27:00","guid":{"rendered":"https:\/\/hispanicprwire.com\/english-if-you-a-child-in-your-care-or-another-loved-one-were-harmed-by-endo-or-a-related-company-including-par-or-ams-or-their-products-including-opioids-ranitidine-or-transvaginal-mesh-your\/"},"modified":"2023-04-25T10:30:07","modified_gmt":"2023-04-25T14:30:07","slug":"si-usted-un-nino-bajo-su-cuidado-u-otro-ser-querido-fue-perjudicado-por-endo-o-una-compania-relacionada-como-par-o-ams-o-por-sus-productos-opioides-ranitidina-o-malla-transvaginal-sus-derechos","status":"publish","type":"post","link":"https:\/\/hispanicprwire.com\/en\/si-usted-un-nino-bajo-su-cuidado-u-otro-ser-querido-fue-perjudicado-por-endo-o-una-compania-relacionada-como-par-o-ams-o-por-sus-productos-opioides-ranitidina-o-malla-transvaginal-sus-derechos\/","title":{"rendered":"IF YOU, A CHILD IN YOUR CARE, OR ANOTHER LOVED ONE WERE HARMED BY ENDO OR A RELATED COMPANY, INCLUDING PAR OR AMS, OR THEIR PRODUCTS INCLUDING OPIOIDS, RANITIDINE, OR TRANSVAGINAL MESH, YOUR RIGHTS MAY BE AFFECTED BY DEADLINES IN THE ENDO BANKRUPTCY."},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen5{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 1pt\n}\n.prngen4{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; BORDER-TOP:black 1pt; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 0.5pt solid\n}\n.prnsblb1{\nBORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prncbts{\nBORDER-TOP:black 0.5pt solid\n}\n.prnbsbls{\nBORDER-LEFT:black 0.5pt solid\n}\n.prnbrbrs{\nBORDER-RIGHT:black 0.5pt solid\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnbbbs{\nBORDER-BOTTOM:black 0.5pt solid\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE; BORDER-TOP:1pt  black; BORDER-RIGHT:1pt  black; BORDER-BOTTOM:1pt  black; BORDER-LEFT:1pt  black\n}\n.prnpr2{\nPADDING-RIGHT:0.17em\n}\n.prnpl2{\nPADDING-LEFT:0.17em\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><b>The deadline to file a claim in the bankruptcy is <span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">5:00 p.m.<\/span> (prevailing Eastern Time).<br \/><\/b><b>The deadline to object to Endo&#8217;s sale is <span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">4:00 p.m.<\/span> (prevailing Eastern Time).<\/b><\/p>\n<p><span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">April 25, 2023<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; The following is being issued by Kroll Restructuring Administration LLC.<\/p>\n<p><b><u>WHAT IS THIS ABOUT?<\/u><\/b><\/p>\n<p>On August\u00a016, 2022, Endo International plc and certain of its affiliates filed for chapter\u00a011 bankruptcy in <span class=\"xn-location\">the United States<\/span> Bankruptcy Court for the Southern District of <span class=\"xn-location\">New York<\/span>. Certain Endo affiliates manufactured and\/or sold, among other things, branded opioid medications (including but not limited to OPANA<sup>\u00ae<\/sup> (oxymorphone hydrochloride), OPANA<sup>\u00ae<\/sup> ER (oxymorphone hydrochloride extended release), and PERCOCET<sup>\u00ae<\/sup> (oxycodone and acetaminophen tablets)), generic opioid medications, generic ranitidine medications, and transvaginal mesh. <b>This notice is intended to inform you of your rights in this bankruptcy regarding the bar date and proof of claim process and Endo&#8217;s proposed sale of substantially all of its assets.<\/b><\/p>\n<p><b><u>WHAT IS A CLAIM?<\/u><\/b><\/p>\n<p>A &#8220;claim&#8221; means a right to seek payment or other compensation. If you, a child in your care, or another loved one were harmed by Endo or a related company, including Par or American Medical Systems (AMS), or their products, including opioids, ranitidine, or transvaginal mesh, you may have a claim against one or more of these entities. To make a claim, you will need to submit a proof of claim in the bankruptcy case. You may file a claim on behalf of yourself, a child in your care (including a child exposed to opioids in the womb), or a deceased or disabled relative. Examples of claims that may be filed in the Endo bankruptcy include but are not limited to:<\/p>\n<ul type=\"disc\">\n<li><b>Opioid Claims<\/b>: Claims for death, addiction or dependence, lost wages, loss of consortium, or neonatal abstinence syndrome (sometimes referred to as &#8220;NAS&#8221;), among others.\n<\/li>\n<li><b>Ranitidine claims<\/b>: Claims for cancer, including bladder, esophageal, pancreatic, stomach, and liver cancer, among others.\n<\/li>\n<li><b>Transvaginal mesh claims<\/b>: Claims for pelvic pain, infection, bleeding, among others.<\/li>\n<\/ul>\n<p><b><u>WHAT DO YOU NEED TO KNOW ABOUT THE BAR DATE AND PROOF OF CLAIM PROCESS?<\/u><\/b><\/p>\n<p><b>The deadline to submit your proof of claim is called a bar date. The bar date<\/b>, or the deadline to submit your proof of claim,<b> is<\/b> <b><span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">5:00 p.m.<\/span> (prevailing Eastern Time)<\/b>. If you do not submit a proof of claim by the deadline, you will lose any rights you may have had to seek payment or compensation. You must file a proof of claim form so that it is <u>actually received<\/u> by the bar date. A proof of claim form can be filed by you, a legal guardian, survivors, or relatives of people who have died or are disabled. You do not need an attorney to file a proof of claim for you.<\/p>\n<p>For a more complete list of relevant companies and products manufactured and\/or sold by Endo and its related companies, including full prescribing information and BOXED WARNINGS for OPANA<sup>\u00ae<\/sup> (oxymorphone hydrochloride), OPANA<sup>\u00ae<\/sup> ER (oxymorphone hydrochloride extended release), and PERCOCET<sup>\u00ae<\/sup> (oxycodone and acetaminophen tablets), and for more complete details about the bar date and instructions on how to file a confidential personal injury claim, visit <b>EndoClaims.com<\/b> or call <b>877.542.1878 (Toll-Free)<\/b> or <b>929.284.1688 (International)<\/b>.<\/p>\n<p><b><u>WHAT DO YOU NEED TO KNOW ABOUT THE SALE?<\/u><\/b><\/p>\n<p>Endo intends to sell substantially all of its assets in an auction and sale process in the bankruptcy case and subject to approval by the bankruptcy court. <b>Endo is seeking relief that the sale will be free and clear of all claims, liens, and encumbrances.<\/b><\/p>\n<p>If you disagree with the proposed sale, you must object to the sale in writing, so that your objection is received on or before <b><span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">4:00 p.m.<\/span> (prevailing Eastern Time)<\/b>. <b>Any party in interest who fails to properly file and serve its objection by the objection deadline may lose its claim against Endo&#8217;s assets if the sale is approved.<\/b> Objections not filed and served properly may not be considered by the bankruptcy court.<\/p>\n<p>Complete details about the proposed sale, including any auction for Endo&#8217;s assets, the date of the hearing to consider the sale, and instructions on how to file an objection, are available at <b>EndoClaims.com<\/b> or by calling <b>877.542.1878 (Toll-Free)<\/b> or <b>929.284.1688 (International)<\/b>.<\/p>\n<p class=\"prntac\"><b>IF YOU HAVE ANY QUESTIONS OR IF YOU WOULD LIKE TO OBTAIN ADDITIONAL INFORMATION:<\/b><\/p>\n<div>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prnpr2 prnpl2 prnvat prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Call:<\/b><\/span><\/p>\n<\/td>\n<td class=\"prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">877.542.1878 (Toll-Free)<br \/><\/span><span class=\"prnews_span\">929.284.1688 (International)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Write:<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Endo International plc Claims Processing Center <br \/>c\/o Kroll Restructuring Administration LLC <br \/>Grand Central Station, PO Box 4850<br \/><\/span><span class=\"prnews_span\">New York, NY 10163-4850<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Visit:<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EndoClaims.com<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Email:<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EndoInquiries@ra.kroll.com<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<p>SOURCE  Kroll Restructuring Administration LLC<\/p>\n<\/div>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><b>The deadline to file a claim in the bankruptcy is <span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">5:00 p.m.<\/span> (prevailing Eastern Time).<br \/><\/b><b>The deadline to object to Endo&#8217;s sale is <span class=\"xn-chron\">July 7, 2023<\/span>, at <span class=\"xn-chron\">4:00 p.m.<\/span> (prevailing Eastern Time).<\/b><\/p>\n<p><span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">April 25, 2023<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; The following is being issued by Kroll Restructuring Administration LLC.<\/p>\n<p><b><u>WHAT IS THIS&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-144141","post","type-post","status-publish","format-standard","hentry","category-salud"],"acf":[],"_links":{"self":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/144141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/comments?post=144141"}],"version-history":[{"count":"1","href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/144141\/revisions"}],"predecessor-version":[{"id":144142,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/144141\/revisions\/144142"}],"wp:attachment":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media?parent=144141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/categories?post=144141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/tags?post=144141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}